ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation

Bidwell, L. Cinnamon; Karoly, Hollis C.; Hutchison, Kent E.; Bryan, Angela D.

doi:10.1016/j.drugalcdep.2017.06.020

Cited by 14 publications

(12 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Considering that patients with ADHD tend to act impulsively, they may be more likely to abandon treatment, although limited information has been reported linking the effect of ADHD symptomatology in the treatment of comorbid psychopathology, in terms of dropout. These studies were mostly focused on substance use disorder (SUD), such as tobacco [ 38 ] or cocaine [ 39 , 40 , 41 ]. When SUD and ADHD are co-morbid, some factors seem to increase the risk of dropout, including: disruptive behaviors related to ADHD [ 40 ], cognitive deficit (e.g., executive dysfunctions) and the type of substance of abuse [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Does ADHD Symptomatology Influence Treatment Outcome and Dropout Risk in Eating Disorders? A longitudinal Study

Testa

Baenas

Vintró-Alcáraz

et al. 2020

JCM

View full text Add to dashboard Cite

Attention-deficit/hyperactivity disorder (ADHD) and its symptoms have been shown to be present in patients with eating disorders (EDs) and are associated with increased psychopathology and more dysfunctional personality traits. This study aimed to assess if the presence of ADHD symptoms in patients with EDs affects their short and long-term therapy outcome. A total of 136 consecutively treated ED patients were considered in this study. Baseline pre-treatment evaluation included the Adult ADHD Self-Report Scale (ASRS v1.1) for ADHD symptoms and the assessment of eating symptomatology using the Eating Disorders Inventory (EDI-2). Treatment outcome was evaluated in terms of ED symptoms after cognitive behavioral therapy (CBT) and dropout rate during treatment. Furthermore, we evaluated ED symptoms in treatment completers after a follow-up of 8 years on average. Path analyses assessed the potential mediational role of the EDI-2 total score in the relationship between ADHD and treatment outcome. Results showed that baseline symptoms of ADHD indirectly affected treatment outcome after CBT; the ASRS positive screening was related to higher eating symptomatology (standardized coefficient B = 0.41, p = 0.001, 95% CI: 0.26 to 0.55), and the presence of high ED levels contributed to the increase of dropout (B = 0.15, p = 0.041, 95% CI: 0.03 to 0.33) and a worse treatment outcome (B = 0.18, p = 0.041, 95% CI: 0.01 to 0.35). No direct effect was found between the ASRS positive screening with the risk of dropout (B = −0.08, p = 0.375) and worse treatment outcome (B = −0.07, p = 0.414). These results suggest the relevance of identifying specific treatment approaches for patients with ADHD symptoms and severe eating symptomatology.

show abstract

Section: Discussionmentioning

confidence: 99%

Does ADHD Symptomatology Influence Treatment Outcome and Dropout Risk in Eating Disorders? A longitudinal Study

Testa

Baenas

Vintró-Alcáraz

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…В работе Heydary (2012) также не было достаточно информации, чтобы определить, какая именно абстиненция была измерена [44]. Исключены три исследования, в которых изучали только снижение числа выкуриваемых сигарет [10,47,96]. Исключено исследование «программируемого срыва»: после курса варениклина субъектам предлагали выкурить две сигареты, а затем оценивали абстиненцию и удовольствие от курения [64].…”

Section: Introductionunclassified

“…Cytisine overcame placebo in the 12, 24 and 52 weeks of therapy with the following odds ratios (ORs) for abstinence: 3.3 (95% CrI 1.8-5.8), 3.9 (2.4-6.7), 3.8 (CrI 1. [3][4][5][6][7][8][9][10][11]9) accordingly. Varenicline in 2 mg/day dose overcame placebo in the 12, 24 and 52 weeks of therapy with the ORs: 4.0 (3.3-4.7), 3.1 (2.5-3.7), 2.9 (2.2-4.1) accor-dingly.…”

mentioning

confidence: 99%

Network meta-analysis: a comparison of effectiveness and safety of partial agonists of nicotinic acetylcholine receptors varenicline and cytisine for smoking cessation

Radchenko

Владимировна²,

Sykhovskaya

et al. 2018

Rev Clin Pharm Drug Ther

View full text Add to dashboard Cite

Background. Partial agonists of α4b2 nicotinic acetylcholine receptors are the most effective treatment strategy for tobacco smoking cessation. They are able to alleviate withdrawal symptoms and to reduce smoking satisfaction. The aim of this study was to review the efficacy and safety of nicotinic receptor partial agonists varenicline and cytisine, for smoking cessation. Methods. A search for randomized controlled trials was done using the terms (“cytisine”, “tabex”, “varenicline” or 'partial agonists of nicotinic receptors’) in MEDLINE, EMBASE, eLibrary in May 2018. Types of participants, the doses and duration of the treatments, efficacy and safety parameters, quality of randomization and blinding procedures were evaluated. Bayesian network meta-analysis was performed. Results. Cytisine overcame placebo in the 12, 24 and 52 weeks of therapy with the following odds ratios (ORs) for abstinence: 3.3 (95% CrI 1.8–5.8), 3.9 (2.4–6.7), 3.8 (CrI 1.3–11,9) accordingly. Varenicline in 2 mg/day dose overcame placebo in the 12, 24 and 52 weeks of therapy with the ORs: 4.0 (3.3–4.7), 3.1 (2.5–3.7), 2.9 (2.2–4.1) accor dingly. Varenicline in 1 mg/day dose overcame placebo in 12 and 52 weeks of therapy, the ORs were 3.0 (2.0–4.7) and 2.3 (1.3–4.4) accordingly. Varenicline in 0.5 mg/day dose overcame placebo in 12 weeks of therapy only with the OR 2.4 (1.3–4.4). Cytisine and varenicline 2 mg/day were associated with more gastrointestinal disturbances than placebo with the ORs 6.2 (2.1–22.8) and 2.4 (2.0–2.8) accordingly. Cytisine and varenicline 2 mg/day were associated with more psychiatric problems than placebo with ORs 5.2 (1.9–15.1) and 1.6 (1.3–1.9) accordingly. There was no difference in serious adverse events between the investigated drugs and placebo: OR for cytisine was 2.4 (0.8–6.8), varenicline 0.5 mg/day – 2.0 (0.5–6.6), varenicline 1.0 mg/day – 1.0 (0.3–2.7), varenicline 2 mg/day – 1.0 (0.7–1.4). Conclusion. Cytisine was proved to be as effective and safe aid for smoking cessation as varenicline.

show abstract

“…Varenicline is a synthetic chemical substance produced from the alkaloid cytisine, which acts as a partial agonist for α4β2 and α3β4 nicotinic cholinergic receptors and as a total agonist for α7 receptor . This substance has a higher smoking cessation rate than other methods, such as nicotine replacement (patch, nicotine gum and spray) and other medications (bupropion and cytisine) .…”

mentioning

confidence: 99%

“…As a partial agonist, varenicline acts in two ways to exert its therapeutic effect: (1) It binds to nicotinic cholinergic receptors, activating them, which leads to the release of dopamine, promoting the same effects of nicotine, but at a much lower intensity, and without the effects of abstinence (agonist effect); (2) it prevents exogenous nicotine from binding to nicotinic cholinergic receptors, blocking the reinforcing effects of its continuous use (antagonistic effect) .…”

mentioning

confidence: 99%

Evaluation of Prolonged Exposure to Varenicline in Adult Rats: Haematological, Biochemical and Anatomopathological Studies

Zaccarelli-Magalhães

Moreira

Sandini

et al. 2017

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Varenicline is a synthetic chemical substance produced from the alkaloid cytisine, used for smoking treatment, which acts as a partial agonist for α4β2 and α3β4 nicotinic cholinergic receptors and as a total agonist for α7 receptor. While there are studies regarding varenicline's non-smoking-related effects, as in treatment for drug dependence, there are no studies in the literature evaluating the long-term toxicity of varenicline through a physiological approach. Thus, the aim of this study was to evaluate possible toxicity through haematological, biochemical and anatomopathological parameters of prolonged exposure (30 days) to varenicline in rats. Three doses of varenicline were used: 0.03 (therapeutic dose for human beings), 0.1 and 0.3 mg/kg orally (gavage). Body-weight, water and food intake were measured weekly during treatment. On the 30th treatment day, blood and various organs were collected for haematological, biochemical and anatomopathological evaluations. The results show a decrease in some biochemical parameters in animals from the 0.1 and 0.3 mg/kg group, although the values are within the normal range of the species. There were no changes in the other evaluations performed. Together, these data indicate that prolonged exposure of rats to different doses of varenicline was not able to alter haematological, biochemical and anatomopathological parameters.

show abstract

ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation

Cited by 14 publications

References 53 publications

Does ADHD Symptomatology Influence Treatment Outcome and Dropout Risk in Eating Disorders? A longitudinal Study

Does ADHD Symptomatology Influence Treatment Outcome and Dropout Risk in Eating Disorders? A longitudinal Study

Network meta-analysis: a comparison of effectiveness and safety of partial agonists of nicotinic acetylcholine receptors varenicline and cytisine for smoking cessation

Evaluation of Prolonged Exposure to Varenicline in Adult Rats: Haematological, Biochemical and Anatomopathological Studies

Contact Info

Product

Resources

About